BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

18039

540025

ADVENZYMES

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

ADVANCED ENZYME TECH LTD performance

Today’s low

Today’s high

₹ 283.45 ₹ 299.75
₹ 289.00

52 week low

52 week high

₹ 257.90 ₹ 571.00
₹ 289.00

Open Price

₹ 298.90

Prev. Close

₹ 298.25

Volume (Shares)

92612.00

Total traded value

₹ 267.64

Upper Circuit

₹ 357.90

Lower Circuit

₹ 238.60

info

ADVANCED ENZYME TECH LTD Share Price Update

As of the latest trading session, ADVANCED ENZYME TECH LTD share price is currently at ₹ 287.1, which is down by ₹ -11.14 from its previous closing. Today, the stock has fluctuated between ₹ 283.45 and ₹ 299.75. Over the past year, ADVANCED ENZYME TECH LTD has achieved a return of -22.62 %. In the last month alone, the return has been 0.79 %. Read More...

ADVANCED ENZYME TECH LTD fundamentals


  • Market cap (Cr)

    3,210.46

  • P/E Ratio (TTM)

    35.30

  • Beta

    0.79

  • Book Value / share

    53.81

  • Return on equity

    22.29%

  • EPS (TTM)

    9.47

  • Dividend yield

    1.71%

  • Net profit/quarter (Cr)

    15.18

info icon alternate text
  • Market cap (Cr)

    3,221.09

  • P/E Ratio (TTM)

    35.30

  • Beta

    0.71

  • Book Value / share

    53.81

  • Return on equity

    22.29%

  • EPS (TTM)

    9.47

  • Dividend yield

    1.71%

  • Net profit/quarter (Cr)

    15.18

info icon alternate text

ADVANCED ENZYME TECH LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 100.87
Operating Expense 81.76
Net Profit 15.18
Net Profit Margin (%) 15.04
Earnings Per Share (EPS) 1.36
EBITDA 23.49
Effective Tax Rate (%) 26.09
Particulars SEP 2024 (Values in Cr)
Revenue 77.38
Operating Expense 66.72
Net Profit 9.13
Net Profit Margin (%) 11.79
Earnings Per Share (EPS) 0.82
EBITDA 15.18
Effective Tax Rate (%) 25.97
Particulars JUN 2024 (Values in Cr)
Revenue 85.96
Operating Expense 67.67
Net Profit 67.06
Net Profit Margin (%) 78.01
Earnings Per Share (EPS) 6.00
EBITDA 74.80
Effective Tax Rate (%) 7.06
Particulars MAR 2024 (Values in Cr)
Revenue 92.40
Operating Expense 66.28
Net Profit 3.14
Net Profit Margin (%) 3.39
Earnings Per Share (EPS) 0.28
EBITDA 13.51
Effective Tax Rate (%) 69.77
Particulars DEC 2023 (Values in Cr)
Revenue 91.14
Operating Expense 69.35
Net Profit 19.12
Net Profit Margin (%) 20.97
Earnings Per Share (EPS) 1.71
EBITDA 28.11
Effective Tax Rate (%) 24.60
Particulars MAR 2024 (Values in Cr)
Revenue 365.47
Operating Expense 271.34
Net Profit 108.12
Net Profit Margin (%) 29.58
Earnings Per Share (EPS) 9.67
EBITDA 145.05
Effective Tax Rate (%) 19.30
Particulars MAR 2023 (Values in Cr)
Revenue 311.53
Operating Expense 247.05
Net Profit 55.53
Net Profit Margin (%) 17.82
Earnings Per Share (EPS) 4.97
EBITDA 84.70
Effective Tax Rate (%) 25.24
Particulars MAR 2022 (Values in Cr)
Revenue 272.80
Operating Expense 209.81
Net Profit 54.51
Net Profit Margin (%) 19.98
Earnings Per Share (EPS) 4.88
EBITDA 81.72
Effective Tax Rate (%) 24.36
Particulars MAR 2021 (Values in Cr)
Revenue 283.47
Operating Expense 191.87
Net Profit 71.01
Net Profit Margin (%) 25.05
Earnings Per Share (EPS) 6.36
EBITDA 107.54
Effective Tax Rate (%) 27.85
Particulars MAR 2020 (Values in Cr)
Revenue 247.35
Operating Expense 180.50
Net Profit 57.96
Net Profit Margin (%) 23.43
Earnings Per Share (EPS) 5.19
EBITDA 85.75
Effective Tax Rate (%) 23.59
Particulars MAR 2024 (Values in Cr)
Book Value / Share 118.41
ROE % 10.70
ROCE % 14.53
Total Debt to Total Equity 0.03
EBITDA Margin 36.41
Particulars MAR 2023 (Values in Cr)
Book Value / Share 110.45
ROE % 8.94
ROCE % 12.02
Total Debt to Total Equity 0.03
EBITDA Margin 33.09
Particulars MAR 2022 (Values in Cr)
Book Value / Share 97.37
ROE % 12.02
ROCE % 16.38
Total Debt to Total Equity 0.03
EBITDA Margin 39.48
Particulars MAR 2021 (Values in Cr)
Book Value / Share 86.90
ROE % 16.71
ROCE % 22.70
Total Debt to Total Equity 0.03
EBITDA Margin 48.11
Particulars MAR 2020 (Values in Cr)
Book Value / Share 75.18
ROE % 17.52
ROCE % 22.99
Total Debt to Total Equity 0.04
EBITDA Margin 47.08
Particulars MAR 2024 (Values in Cr)
Book Value / Share 51.91
ROE % 22.29
ROCE % 27.61
Total Debt to Total Equity 0.00
EBITDA Margin 44.93
Particulars MAR 2023 (Values in Cr)
Book Value / Share 46.98
ROE % 11.04
ROCE % 14.76
Total Debt to Total Equity 0.00
EBITDA Margin 27.25
Particulars MAR 2022 (Values in Cr)
Book Value / Share 42.97
ROE % 11.90
ROCE % 15.71
Total Debt to Total Equity 0.00
EBITDA Margin 30.02
Particulars MAR 2021 (Values in Cr)
Book Value / Share 38.97
ROE % 17.62
ROCE % 23.93
Total Debt to Total Equity 0.01
EBITDA Margin 37.98
Particulars MAR 2020 (Values in Cr)
Book Value / Share 33.17
ROE % 16.80
ROCE % 21.12
Total Debt to Total Equity 0.04
EBITDA Margin 34.75
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 143.49
Total Assets 1535.46
Total Liabilities 1535.46
Total Equity 1371.08
Share Outstanding 111824075
Price to Book Ratio 6.69
Return on Assets (%) 8.68
Return on Capital (%) 9.55
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 123.34
Total Assets 1421.84
Total Liabilities 1421.84
Total Equity 1284.17
Share Outstanding 111824075
Price to Book Ratio 4.93
Return on Assets (%) 7.42
Return on Capital (%) 8.14
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 273.63
Total Assets 1267.60
Total Liabilities 1267.60
Total Equity 1140.38
Share Outstanding 111800675
Price to Book Ratio 6.57
Return on Assets (%) 9.43
Return on Capital (%) 10.39
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 197.77
Total Assets 1156.17
Total Liabilities 1156.17
Total Equity 1032.62
Share Outstanding 111728425
Price to Book Ratio 8.85
Return on Assets (%) 12.62
Return on Capital (%) 13.88
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 83.02
Total Assets 978.60
Total Liabilities 978.60
Total Equity 867.44
Share Outstanding 111678475
Price to Book Ratio 4.32
Return on Assets (%) 13.21
Return on Capital (%) 14.62
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 18.56
Total Assets 632.93
Total Liabilities 632.93
Total Equity 580.47
Share Outstanding 111824075
Price to Book Ratio 6.69
Return on Assets (%) 17.08
Return on Capital (%) 18.63
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 24.72
Total Assets 575.80
Total Liabilities 575.80
Total Equity 525.33
Share Outstanding 111824075
Price to Book Ratio 4.93
Return on Assets (%) 9.64
Return on Capital (%) 10.57
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 17.97
Total Assets 529.62
Total Liabilities 529.62
Total Equity 480.35
Share Outstanding 111800675
Price to Book Ratio 6.57
Return on Assets (%) 10.29
Return on Capital (%) 11.34
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.87
Total Assets 489.60
Total Liabilities 489.60
Total Equity 435.44
Share Outstanding 111728425
Price to Book Ratio 8.85
Return on Assets (%) 14.50
Return on Capital (%) 16.27
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 3.02
Total Assets 422.67
Total Liabilities 422.67
Total Equity 370.48
Share Outstanding 111678475
Price to Book Ratio 4.32
Return on Assets (%) 13.71
Return on Capital (%) 15.29
Particulars MAR 2024 (Values in Cr)
Net Income 187.82
Cash from Operations 190.60
Cash from Investing -64.64
Cash from Financing -59.23
Net change in Cash 17.48
Free Cash Flow 237.86
Particulars MAR 2023 (Values in Cr)
Net Income 140.38
Cash from Operations 177.00
Cash from Investing -298.18
Cash from Financing -25.79
Net change in Cash -183.61
Free Cash Flow 215.10
Particulars MAR 2022 (Values in Cr)
Net Income 171.05
Cash from Operations 176.82
Cash from Investing -3.78
Cash from Financing -48.50
Net change in Cash 70.00
Free Cash Flow 204.93
Particulars MAR 2021 (Values in Cr)
Net Income 210.13
Cash from Operations 219.67
Cash from Investing -26.03
Cash from Financing -26.38
Net change in Cash 110.54
Free Cash Flow 239.12
Particulars MAR 2020 (Values in Cr)
Net Income 179.15
Cash from Operations 191.79
Cash from Investing -44.49
Cash from Financing -38.55
Net change in Cash 57.84
Free Cash Flow 242.44
Particulars MAR 2024 (Values in Cr)
Net Income 133.99
Cash from Operations 83.01
Cash from Investing -6.88
Cash from Financing -56.88
Net change in Cash -7.95
Free Cash Flow 103.62
Particulars MAR 2023 (Values in Cr)
Net Income 74.27
Cash from Operations 66.75
Cash from Investing -42.35
Cash from Financing -11.99
Net change in Cash -4.04
Free Cash Flow 90.17
Particulars MAR 2022 (Values in Cr)
Net Income 72.07
Cash from Operations 58.54
Cash from Investing -14.23
Cash from Financing -10.87
Net change in Cash 11.99
Free Cash Flow 69.08
Particulars MAR 2021 (Values in Cr)
Net Income 98.42
Cash from Operations 111.05
Cash from Investing -69.90
Cash from Financing -15.48
Net change in Cash -1.16
Free Cash Flow 120.52
Particulars MAR 2020 (Values in Cr)
Net Income 75.85
Cash from Operations 58.67
Cash from Investing -24.93
Cash from Financing -18.55
Net change in Cash 2.48
Free Cash Flow 99.52
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 39.43 21.20 2.15 302.17 34.11 / 77.70
BLISS GVS PHARMA LTD 126.30 16.55 1.31 1330.83 92.25 / 184.95
CIPLA LTD 1551.30 25.11 4.41 125285.64 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 289.65 24.00 2.93 852.47 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 39.43 23.75 6.70 302.17 34.11 / 77.70
AMRUTAJAN HEALTH LTD 672.50 39.42 6.52 1944.24 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8961.95 133.66 32.97 22404.88 5000.00 / 9199.00
BLISS GVS PHARMA LTD 126.30 16.40 1.29 1330.83 92.25 / 184.95

ADVANCED ENZYME TECH LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
289.00 -3.10 redarrow
red-green-graph indicator
9 Bearish
7 Bullish
  • 5 Days 296.10
  • 26 Days 288.20
  • 10 Days 291.90
  • 50 Days 296.10
  • 12 Days 290.80
  • 100 Days 322.10
  • 20 Days 288.20
  • 200 Days 349.50
298.15 PIVOT

First Support

292.75

First Resistance

302.00

Second Support

288.90

Second Resistance

307.40

Third Support

283.50

Third Resistance

311.25

RSI

57.28

ADX

21.30

MACD

2.61

Williams % R

-20.37

Commodity Channel Index (CCI)

105.90

Date

2025-04-24

Week

60498.00

Same Day

65924.00

Month

80408.00

1 Year

0.80

3 Year

0.77

Over 1 Month

0.79%

down

Over 1 Year

-22.62%

down

Over 3 Months

-8.98%

down

Over 3 Years

-0.53%

down

Over 6 Months

-31.12%

down

Over 5 Years

16.19%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

ADVANCED ENZYME TECH LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
36.83%
Promoter Holdings
43.08%
FII
11.89%
DII
8.18%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Vasant Rathi 3.7123702E7 (33.18%) Shareholding of Promoter and Promoter Group
Orbimed Asia Iii Mauritius Fvci Limited 1.3509522E7 (12.07%) Public Shareholding
Nalanda India Equity Fund Limited 9465501.0 (8.46%) Public Shareholding
Icici Prudential Pharma Healthcare And Diaganostics (p.h.d) Fund 3447631.0 (3.08%) Public Shareholding
Rasika Vasant Rathi 2665825.0 (2.38%) Shareholding of Promoter and Promoter Group
Reshma Namita Rathi 2646858.0 (2.37%) Shareholding of Promoter and Promoter Group
Rachana Vasant Rathi 2641500.0 (2.36%) Shareholding of Promoter and Promoter Group
Clarus Capital I 2403864.0 (2.15%) Public Shareholding
Pradip Bhailal Shah 1903400.0 (1.7%) Public Shareholding
Mukund Madhusudan Kabra 1824250.0 (1.63%) Public Shareholding
Marval Guru Fund 1120000.0 (1.0%) Public Shareholding
Kishor Laxminarayan Rathi Huf 1100000.0 (0.98%) Shareholding of Promoter and Promoter Group
Prabhavati Vasant Rathi 913000.0 (0.82%) Shareholding of Promoter and Promoter Group
Madhusudan Kabra 615600.0 (0.55%) Shareholding of Promoter and Promoter Group
Kishor Laxminarayan Rathi 406000.0 (0.36%) Shareholding of Promoter and Promoter Group
Jayesh Madhusudan Soni 35000.0 (0.03%) Shareholding of Promoter and Promoter Group
Megha Jhawar 20000.0 (0.02%) Shareholding of Promoter and Promoter Group
Payal Akshay Kulkarni 7500.0 (0.01%) Shareholding of Promoter and Promoter Group
Snehal Shamsunder Soni 15000.0 (0.01%) Shareholding of Promoter and Promoter Group
Atharva Green Ecotech Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Advanced Vital Enzymes Pvt Ltd 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Pramila Shamsunder Soni 5000.0 (0.0%) Shareholding of Promoter and Promoter Group
Sunil Ramdayal Attal 5000.0 (0.0%) Shareholding of Promoter and Promoter Group
Piyush Chandrakumar Rathi 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Radhika Ashish Pujara 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Chandrakumar Laxminarayan Rathi 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Savita Chandrakumar Rathi 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

ADVANCED ENZYME TECH LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
04 Aug 2023 1.0 Final 05 Aug 2023 Equity shares
19 May 2023 4.0 Interim 20 May 2023 Equity shares
11 Aug 2022 1.0 Final 12 Aug 2022 Equity shares
31 Aug 2021 0.9 Final 01 Sep 2021 Equity shares
09 Jul 2020 0.6 Final 11 Jul 2020 Equity shares
01 Aug 2019 0.6 Final 03 Aug 2019 Equity shares
06 Sep 2018 0.5 Final 08 Sep 2018 Equity shares
04 Sep 2017 0.4 Final 06 Sep 2017 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
25 May 2017 10.0 2.0 26 May 2017
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
17 May 2024 4.0 Interim 18 May 2024 Equity shares
04 Aug 2023 1.0 Final 05 Aug 2023 Equity shares
19 May 2023 4.0 Interim 20 May 2023 Equity shares
11 Aug 2022 1.0 Final 12 Aug 2022 Equity shares
31 Aug 2021 0.9 Final 01 Sep 2021 Equity shares
09 Jul 2020 0.6 Final 11 Jul 2020 Equity shares
01 Aug 2019 0.6 Final 03 Aug 2019 Equity shares
06 Sep 2018 0.5 Final 08 Sep 2018 Equity shares
04 Sep 2017 0.4 Final 06 Sep 2017 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
25 May 2017 10.0 2.0 26 May 2017

ADVANCED ENZYME TECH LTD Share Price

Advanced Enzyme Technologies Limited (AETL) is largest Indian enzyme company that has transformed business globally in the manufacturing and sale of enzymes. Advanced Enzyme Technologies Limited was incorporated, as a Private Company on March 15, 1989 as 'Advanced Biochemicals Private Limited' in Maharashtra. The Company thereafter, got converted into a Public Company and the name of the Company changed to Advanced Biochemicals Limited on May 28, 1992. Again, the name was changed to Advanced Enzyme Technologies Limited and a fresh Certificate of Incorporation was issued by the Registrar of Companies, Mumbai on August 19, 2005.

In 2011, the company took over Cal-India Foods International, giving the company direct presence in USA.

In 2012, the company took over Advanced Supplementary Technologies Corporation for consolidating its presence in USA.

Advanced Enzyme Technologies Limited came out with its Initial Public Offer (IPO) of 4,594,875 Equity shares of Rs 10 each at an issue price of Rs 896 per Equity share ( Rs 810 per Equity share for eligible employees), consisting of fresh issue of 560,405 Equity shares and an Offer for Sale of 4,034,470 Equity shares by Selling Shareholders. The IPO was open for subscription during the period from 20 July 2016 to 22 July 2016. The said offer was overall subscribed 82.06 times. The equity shares of Advanced Enzyme Technologies Limited were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 1 August 2016 at an opening market price of Rs 1,210 on both the exchanges compared with the IPO price of Rs 896 per share.

During the financial year ended 31 March 2017, Advanced Enzyme Technologies Limited acquired 1.43 crore equity shares at Rs 35 per share of JC Biotech Private Limited (JCB), aggregating to Rs 50.08 crore, 70% of the paid-up share capital of JCB. In view of this JCB became subsidiary with effect from December 1, 2016.

The sub-division of equity shares of the company from face value of 10 each to face value of 2 each (Stock Split) and consequent alteration in Capital Clause of Memorandum of Association of was approved by the company's shareholders on May 04, 2017, through a Postal Ballot. The Record Date' for the purpose of ascertaining the shareholders entitled to receive the said sub-divided equity shares was fixed by the Board as May 26, 2017. Subsequently, the company issued five (5) sub-divided equity shares of 2 each in lieu of one (1) equity share of 10 each to the eligible shareholders of the company.

On 3 July 2017, Advanced Enzyme Technologies completed the acquisition of 200,000 equity shares of MYR 1 (Malaysia Ringgit) each aggregating to MYR 200,000 (equivalent to approx. 3,134,000) of AEM i.e. 80% of paid-up share capital of AEM. The company also subscribed to right issue of 150,000 Equity Shares at MYR 1 per share of AEM, aggregating to MYR 150,000 (equivalent to 2,602,500) on 13 March 2018. On 20 March 2018, the company completed the acquisition of remaining stake i.e. 50,000 equity shares of face value of MYR 1 each of AEM. The said acquisition was made at face value for a total consideration of MYR 50,000 (equivalent to 867,800). In view of the above, AEM has become a wholly-owned subsidiary of the company, effective from March 30, 2018.

The company's wholly owned subsidiary, Advanced Enzymes Europe BV acquired 100% stake in evoxx technologies GmbH (evoxx) and evoxx became a step-down subsidiary of the Company in 2020-21.

In January 2021, it completed the acquisition of controlling stake of 51% in SciTech Specialities Private Limited (SSPL), India, a contract manufacturing company specializing in effervescent granules and tablets with 2 manufacturing facilities and 1 R&D unit, which became a subsidiary of Company effective from January 11, 2021. On 29 May 2021, Company acquired additional stake of 15% from existing shareholders of JC Biotech Private Limited (JCB) at a consideration of Rs. 211.25 Million. The said acquisition by increase in stake in JCB was completed on August 18, 2021 and the stake of Company in JCB increased from existing 70% to 85%.

In 2023, the Company acquired an additional stake of 4.83% in subsidiary, JC Biotech, resulting in a total stake of 89.83%. It acquired 50% stake in Saiganesh Enzytech Solutions Private Limited on 03 January 2023 and it became a subsidiary of the Company. The Company launched Wellfa, a B2C consumer brand and further introduced new products including enzymes for producing chiral/ non-chiral molecules; Pepzyme Pro, clinically proven product for optimizing protein digestion, uptake, and gut modulation; SacchariSEB ML for easily absorbable dietary fiber production; and Code T-400, designed to enhance tea properties.

Further, the Company acquired additional stake of 5.89% in its subsidiary JC Biotech Private Limited effective on March 5, 2024 and post the additional acquisition, the Company holds 95.72% stake in the subsidiary.

Parent organization Indian Private
NSE symbol ADVENZYMES
Founded 1989
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Advanced Enzyme Technologies Ltd?

Answer Field

The share price of Advanced Enzyme Technologies Ltd for NSE is ₹ 287.1 and for BSE is ₹ 288.05.

What is the Market Cap of Advanced Enzyme Technologies Ltd?

Answer Field

The market cap of Advanced Enzyme Technologies Ltd for NSE is ₹ 32,10.46 Cr. and for BSE is ₹ 32,21.09 Cr. as of now.

What is the 52 Week High and Low of Advanced Enzyme Technologies Ltd?

Answer Field

The 52 Week High and Low of Advanced Enzyme Technologies Ltd for NSE is ₹ 571.00 and ₹ 257.90 and for BSE is ₹ 571.15 and ₹ 257.85.

How to Buy Advanced Enzyme Technologies Ltd share?

Answer Field

You can trade in Advanced Enzyme Technologies Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Advanced Enzyme Technologies Ltd?

Answer Field

The 1 year returns on the stock has been -22.62%.

What is the Current Share Price of Advanced Enzyme Technologies Ltd?

Answer Field

Advanced Enzyme Technologies Ltd share price is for NSE ₹ 287.1 & for BSE ₹ 288.05 as on Apr 25 2025 03:29 PM.

What is the Market Cap of Advanced Enzyme Technologies Ltd Share?

Answer Field

The market cap of Advanced Enzyme Technologies Ltd for NSE ₹ 32,10.46 & for BSE ₹ 32,21.09 as on Apr 25 2025 03:29 PM.

What is the P/E Ratio of Advanced Enzyme Technologies Ltd Share?

Answer Field

As on Apr 25 2025 03:29 PM the price-to-earnings (PE) ratio for Advanced Enzyme Technologies Ltd share is 35.30.

What is the PB ratio of Advanced Enzyme Technologies Ltd Share?

Answer Field

As on Apr 25 2025 03:29 PM, the price-to-book (PB) ratio for Advanced Enzyme Technologies Ltd share is 53.81.

How to Buy Advanced Enzyme Technologies Ltd Share?

Answer Field

You can trade in Advanced Enzyme Technologies Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Advanced Enzyme Technologies Ltd Share on Bajaj Broking App?

Answer Field

To buy Advanced Enzyme Technologies Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Advanced Enzyme Technologies Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|